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Spontaneous pneumothoraces due to lung cyst
rupture afflict patients with the rare disease Birt-
Hogg-Dube´ (BHD) syndrome, which is caused by
mutations of the tumor suppressor gene folliculin
(FLCN). The underlying mechanism of the lung
manifestations in BHD is unclear. We show that
BHD lungs exhibit increased alveolar epithelial cell
apoptosis and that Flcn deletion in mouse lung
epithelium leads to cell apoptosis, alveolar enlarge-
ment, and an impairment of both epithelial barrier
and overall lung function. We find that Flcn-null
epithelial cell apoptosis is the result of impaired
AMPK activation and increased cleaved caspase-3.
AMPK activator LKB1 and E-cadherin are downregu-
lated by Flcn loss and restored by its expression.
Correspondingly, Flcn-null cell survival is rescued
by the AMPK activator AICAR or constitutively active
AMPK. AICAR also improves lung condition of Flcnf/f:
SP-C-Cre mice. Our data suggest that lung cysts in
BHDmay result from an underlying defect in alveolar
epithelial cell survival, attributable to FLCN regula-
tion of the E-cadherin-LKB1-AMPK axis.
INTRODUCTION
Birt-Hogg-Dube´ (BHD) syndrome is a rare autosomal-dominant
disorder that affects lung, skin, and kidney (Birt et al., 1977). In
the lung, 80%–100% of patients with BHD develop multiple
thin-wall cysts without evidence of neoplasia, inflammation, or
fibrosis (Gupta et al., 2013). Cyst rupture and lung collapse cause
spontaneous and recurrent pneumothoraces (Gupta et al.,412 Cell Reports 7, 412–423, April 24, 2014 ª2014 The Authors2013). In contrast to lung, FLCN mutations in the kidney result
in bilateral multifocal renal cell carcinomas (Schmidt, 2004),
and in hair follicles result in hamartomas (fibrofolliculomas).
The mechanism by which the loss of FLCN promotes the devel-
opment of cysts but not neoplasia is unknown.
Genetic mapping in families with BHD identified the Folliculin
(FLCN) gene locus (Nickerson et al., 2002; Schmidt et al.,
2001). Loss of heterozygosity in BHD lesions supports a tumor
suppressor function for FLCN (Vocke et al., 2005). Homozygous
Flcn/mice are embryonically lethal, and heterozygous Flcn+/
mice develop kidney tumors without lung pathology (Hasumi
et al., 2009). In Drosophila and yeast, FLCN is involved in the
mammalian target of rapamycin signaling pathway and in energy
metabolism (Liu et al., 2013; van Slegtenhorst et al., 2007). Inac-
tivation of FLCN inducesmitochondrial gene expression (Hasumi
et al., 2012). Studies also suggest crosstalk of FLCN with the
master energy sensor AMP-activated protein kinase (AMPK)
via FLCN-interacting proteins FNIP1 and FNIP2 (Baba et al.,
2006; Hasumi et al., 2008; Takagi et al., 2008). How these
signaling events relate to FLCN function in normal lung or in
pulmonary cyst development in BHD is unknown.
The prevailing hypothesis used to explain the development
of emphysematous alveolar enlargement and cyst formation in
lung diseases involves an imbalance between matrix degrading
matrix metalloproteinases (MMPs) and their endogenous inhi-
bitors the tissue inhibitor of metalloproteinases (Shapiro and
Ingenito, 2005; Suki et al., 2003). The notion, however, that
alveolar epithelial cell (AEC) apoptosis is a primary event in
the pathogenesis of alveolar enlargement related to lung injury
has become an area of significant interest (Henson and Tuder,
2008; Mouded et al., 2009). The FLCN-dependent mechanism
of cystic lung enlargement in BHD and the functional significance
of FLCN inactivation in the lung remain uncharacterized.
Cell-cell and cell-matrix interactions are critical components
of epithelial cell survival, and disruption of these interactions
Figure 1. Lung Histology and FLCN and
SP-C Immunostaining
(A) H&E staining of normal human lung (Control)
(n = 3) and BHD lung (n = 4). A, conducting air-
ways; V, blood vessels.
(B) FLCN-positive (red) AECs (SP-C, green) are
seen in normal human lung (n = 3), but not in BHD
(n = 4) lungs. DAPI (blue) stains nuclei. Arrows
indicate FLCN immunostaining colocalized with
SP-C expression in AECs in control lungs, but not
in lungs from patients with BHD.
(C) Genotyping of homozygous Flcnf/f:SP-C-Cre
(1), FlcnWT/WT:SP-C-Cre (2), and heterozygous
FlcnWT/f:SP-C-Cre mice (3).
(D) Flcn levels in whole-lung lysates from Flcnf/f:
SP-C-Cre mice on Dox (Dox+) for 6 weeks (n = 3)
or a regular (Dox) diet (n = 3).
(E) Loss of Flcn (red) in lung AECs (SP-C, green) in
Flcnf/f:SP-C-Cre mice treated as in (D). Arrows
indicate FLCN immunostaining colocalized with
SP-C expression in Flcnf/f:SP-C-Cre mice on a
Dox, but not on a Dox+, diet.
Scale bars, 20 mM. See also Figure S1.often leads to caspase-mediated apoptosis (Frisch and Screa-
ton, 2001). AMPK is required for cell survival and for the mainte-
nance of epithelial cell junctions (Hardie, 2011; Lee et al., 2008;
Liu et al., 2010; Zheng and Cantley, 2007). AMPK activity is
regulated through phosphorylation by LKB1 (Hardie, 2011), a
tumor suppressor gene associated with 30% of lung cancers
(Makowski and Hayes, 2008). LKB1 controls the maturation of
apical junctions in human bronchial epithelial cells (Xu et al.,Cell Reports 7, 412–42013). E-cadherin regulates the localiza-
tion of LKB1 to epithelial cell junctions,
and loss of E-cadherin impairs LKB1-
mediated AMPK activation (Sebbagh
et al., 2009).
These observations raise the possibil-
ity that FLCN might be involved in the
regulation of AMPK signaling in AECs
and that inactivating mutation of FLCN
might impair epithelial cell junctions
and cell survival. In this study, we investi-
gate this possibility with cell-type-spe-
cific inducible Flcn deletion in mouse
lung epithelium and with FLCN-null hu-
man and mouse epithelial cell systems.
RESULTS
Loss of Flcn in Lung Epithelium
Results in Increased Alveoli
Hematoxylin and eosin (H&E) staining of
control human lung reveals typical lung
structure (Figure 1A, left). In contrast,
lungs from patients with BHD showed
irregular and disrupted lung parenchyma
(Figure 1A, right). Healthy alveoli are lined
with type I and the surfactant proteinC (SP-C)-expressing type II AECs (Figures S1A and S1B), a
renewable population of progenitors in these distal airspaces.
We used coimmunostaining to determine FLCN expression
in human lung from healthy controls and subjects with BHD. In
control lung, FLCN staining colocalizes with SP-C expression
in AECs (Figure 1B, top). Coimmunostaining of lung tissue
from patients with BHD detects very little FLCN in alveolar
SP-C-positive cells (Figure 1B, bottom).23, April 24, 2014 ª2014 The Authors 413
To evaluate the role of FLCN in lung, we selectively deleted
Flcn in SP-C-expressing alveolar epithelial type II cells (Flcnf/f:
SP-C-Cre) by crossing Flcnf/f mice (Baba et al., 2008) with SP-
C-rtTA/tetO-Cre (line 2) mice (Perl et al., 2009) (Figure S1C) to
generate Flcnf/f:SP-C-Cre mice with inducible Flcn deletion
in SP-C-expressing cells by a dietary supplementation with
doxycycline (Dox) starting at 6 weeks of age. Under this SP-C
promoter, Cre expression is targeted to the AECs in alveoli and
peripheral bronchioles (Perl et al., 2009). Flcnf/f:SP-C-Cre mice
do not exhibit perinatal lethality or reduced survival, and weights
were comparable across Flcnf/f:SP-C-Cre, FlcnWT/WT:SP-C-Cre,
and Flcnf/WT:SP-C-Cre genotypes. The Dox diet did not affect
mouse survival or weights and did not cause pulmonary distress.
Genotyping, immunoblotting, and coimmunostaining analyses
of Flcnf/f:SP-C-Cre mouse lungs confirmed Flcn deletion with
the Dox diet (Figures 1C–1E, bottom). Immunoblotting (Fig-
ure 1D, Dox+ lanes) shows residual Flcn expression in non-SP-
C-expressing cells in whole-lung lysates. Importantly, inflation-
fixed lungs from epithelial-specific Flcn-deleted mice exhibited
alveolar enlargement (Figure 2A).
Morphometric lung measurements of mean linear intercept
(MLI) and mean alveolar airspace area (MAAA) are significantly
larger in lungs of epithelial-specific Flcn-deleted mice than in
lungs of Flcn-expressing Flcnf/f:SP-C-Cre mice (Figures 2B,
2C, and S1D–S1F). However, the overall structure and organiza-
tion of the lungs are nearly normal. The lung alveoli of FlcnWT/WT:
SP-C-Cre or Flcnf/WT:SP-C-Cre mice on a regular or Dox-sup-
plemental diet appear unchanged and comparable with lung
alveoli of Flcnf/f:SP-C-Cre mice on a regular diet.
FLCN Is Required for Postnatal Lung Alveolarization
To determine the role of FLCN during lung development, female
Flcnf/f:SP-C-Cremice were placed on a Dox-supplemented diet
starting at embryonic day 0.5 (E0.5). Newborn pups were viable
and appeared normal with no increased perinatal lethality. How-
ever, postnatal pups with lung epithelial-specific Flcn deletion
exhibited larger alveoli compared to pups with Flcn-expressing
lung epithelium (Figures 2D–2F). These data show develop-
mental changes induced by FLCN deletion in lung epithelium
and suggest a role for FLCN in branching morphogenesis of
the lung.
FLCN Regulates Lung Function
Morphological changes that resemble emphysema, such as
alveolar enlargement, contribute to a decline in lung elastic recoil
and pulmonary function. Lung function tests of adult Flcnf/f:SP-
C-Cre mice fed Dox for 6 weeks were markedly abnormal
compared to age- and gender-matched littermates maintained
on a regular diet. Decreased airway elastance and resistance
and increased dynamic compliance were observed in Flcnf/f:
SP-C-Cre mice with Flcn deletion in lung epithelium compared
to Flcn-expressing controls (Figure 2G).
To determine whether Flcn loss in other lung epithelial cells
might also impair lung function, we generated Flcnf/f:CCSP-Cre
mice with targeted Flcn deletion in lung epithelial cells express-
ing Clara cell secretory protein (CCSP) (Perl et al., 2009) (Figures
S1G and S1H). CCSP-expressing lung epithelial cells localize
in alveoli and bronchioles (Perl et al., 2009). Flcn deletion in414 Cell Reports 7, 412–423, April 24, 2014 ª2014 The AuthorsFlcnf/f:CCSP-Cre mice did not result in differences in the lung
function (Figure S1I) compared to age- and gender-matched
controls. These results demonstrate that lung parenchyma
and function are affected by Flcn deletion specifically in AECs
expressing SP-C, and alveolar epithelium is vulnerable to loss
of FLCN during early lung development as well as in the mature
lung.FLCN Is Required for AEC Survival In Vivo
To evaluate whether apoptosis plays a role in airspace enlarge-
ment in BHD, control and BHD human lung tissues were
immunostained with cleaved caspase-3 antibody. As seen in
Figure 2H, apoptotic SP-C-positive cells were detected in BHD
lung, but not in control human lung. AECs positive for activated
caspase-3 were identified in lungs of Flcnf/f:SP-C-Cre mice
maintained on a Dox diet compared to age- and gender-
matched littermates maintained on a regular diet (Figure 2I).
Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining to assess DNA fragmentation was also de-
tected in human BHD lungs and mouse lungs with deleted
FLCN (Figure S2). Importantly, TUNEL staining colocalizes with
SP-C immunostaining (Figure S2C).FLCN Downregulates LKB1 and Controls AMPK Activity
Because our results show that FLCN regulates AEC survival
in vivo, we sought to identify the mechanism. AMPK activation
is required to maintain epithelial cell-cell junctions, thus preser-
ving epithelial barriers and promoting cell survival (Hardie,
2011). To determine whether FLCN deficiency affects AMPK
activation, we used the FLCN-null human epithelial renal tumor
cell line UOK257 derived from the kidney tumor of a patient
with BHD, and UOK257 cells with stably re-expressed FLCN
(UOK257-2) used as a control (Baba et al., 2006).
AMPK is phosphorylated on Thr172 by LKB1 under conditions
of stress, such as nutrient deprivation. Serum depletion of
FLCN-expressing UOK257-2 cells for 24 and 48 hr resulted in
time-dependent AMPK phosphorylation at Thr172 (Figure 3A).
Phosphorylation of acetyl-coenzyme A-carboxylase (ACC) by
activated AMPK also increased in a time-dependent manner in
FLCN-expressing UOK257-2 cells. In contrast, FLCN-null cells
exhibited reduced AMPK activation and ACC phosphorylation
compared to FLCN-expressing UOK257-2 cells (Figure 3A).
Importantly, serum deprivation also increased cleaved cas-
pase-3 in FLCN-null UOK257 cells, but not in FLCN-expressing
UOK257-2 cells (Figure 3B).
To further examine the effect of FLCN loss on AMPK activation
in lung epithelial cells, we isolated primary mouse AECs from
lungs of Flcnf/f:SP-C-Cre mice. Cells were treated with either
an empty, replication-defective adenovirus or a replication-
defective adenovirus expressing Cre-recombinase to delete
Flcn (Figure 4A). Immunostaining with antibody against T1a, an
AEC marker (Ramirez et al., 2003), showed T1a expression in
primary mouse AECs from Flcnf/f:SP-C-Cre mice (Figure S3).
AMPK(Thr172) phosphorylation was significantly decreased in
Flcn-null AECs in contrast to Flcn-expressing AECs (Figure 4A).
Small interfering RNA (siRNA)-induced Flcn knockdown in
mouse epithelial NMuMG cells also significantly decreased
Figure 2. Loss of FLCN Increases Pulmonary Alveoli, Impairs Lung Function, and Induces AEC Apoptosis
(A–C) Flcn loss results in alveolar enlargement in Flcnf/f:SP-C-Cre mice treated as in Figure 1D.
(D–F) Enlarged alveoli in pups with FLCN deletion in lung epithelium.
In (B), (C), (E), and (F), the mean is shown; error bars represent SE (n > 3). Data for Dox mice are taken as 1-fold.
(G) FLCN deletion in Flcnf/f:SP-C-Cre mice impairs lung function (n = 8 per group). BL, baseline; S, saline.
(H) Cleaved caspase-3-positive (red) cells in lung epithelium (SP-C, green) of BHD lung (n = 5), but not in control (n = 3) lung. Arrows indicate cleaved caspase-3
immunostaining of SP-C-positive cells in lungs from patients with BHD, but not in control lungs. Scale bars, 20 mM.
(I) Loss of Flcn in lung epithelium (SP-C, green) results in AEC apoptosis (red) in lung from Flcnf/f:SP-C-Cremice treated as in Figure 1D (n = 3 per group). Arrows
indicate cleaved caspase-3 immunostaining of SP-C-positive cells in Flcnf/f:SP-C-Cre mice on a Dox+, but not on a Dox, diet. Scale bars, 20 mM.
See also Figure S2.
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Figure 3. FLCN Loss Impairs AMPK Activa-
tion and Upregulates Cleaved Caspase-3
(A) FLCN-null UOK257 and FLCN-expressing
UOK257-2 epithelial cells were serum deprived
(S.D.) in Dulbecco’s modified Eagle’s medium
supplemented with 0.1% BSA. Data are mean ±
SE (n = 3).
(B) Energy depletion of FLCN-null UOK257 cells
upregulates cleaved caspase-3.AMPK(Thr172) phosphorylation compared to cells transfected
with control siRNA (Figure 4B).
We next examined LKB1 levels in cells deficient for FLCN
because LKB1 activates AMPK via phosphorylation at Thr172-
AMPK (Hardie, 2011). LKB1 levels were reduced in primary
AECs after Flcn deletion (Figure 4A). LKB1 levels were also
markedly decreased in NMuMG cells with Flcn knockdown
induced by siRNA (Figure 4B). To further determine whether
LKB1 expression is regulated by FLCN, FLCN-null UOK257
cells were transduced with replication-defective adenovirus
expressing FLCN. FLCN re-expression in FLCN-null UOK257
cells significantly increased LKB1 levels (Figure 4C). Cellular
fractionation showed significantly increased LKB1 levels
induced by FLCN expression not only in cytosol but also in
the membrane fraction (Figure 4C), confirming membrane
localization of LKB1 (Sebbagh et al., 2009; Xu et al., 2013).
These data suggest that FLCN regulates the cellular level and
localization of LKB1.
Regulation of E-Cadherin by FLCN
Evidence demonstrates that E-cadherin regulates membrane
localization of LKB1, which is critical for AMPK activation
(Sebbagh et al., 2009). Therefore, we determined whether
Flcn deletion in primary AECs would affect E-cadherin
expression and/or localization. E-cadherin is significantly416 Cell Reports 7, 412–423, April 24, 2014 ª2014 The Authorsdecreased in the absence of Flcn
expression (Figures 5A–5C). Immuno-
staining also showed marked reduction
of E-cadherin in the adherens junctions
of cellular membranes (Figure 5D, top;
Figures S4A and S4C). ZO-1 staining at
tight junctions, however, appeared un-
changed by Flcn deletion (Figure 5D,
bottom; Figures S4B and S4C). Thus,
FLCN has a specific effect on E-cad-
herin expression and localization to
adherens junctions.
To further determine FLCN’s role in
regulating E-cadherin, we used TSC2-
null kidney epithelial cells, which have
decreased membrane localization of
E-cadherin (Figure 5E) (Barnes et al.,
2010; Kleymenova et al., 2001). Transient
transfection of TSC2-null cells with myc-
tagged FLCN (Figure 5F) increased E-
cadherin membrane localization, which
was statistically significant (Figure 5G).These data further suggest that FLCN may play a role in regu-
lation of E-cadherin.
Increased FLCN-Null Epithelial Cell Permeability
and Apoptosis
Epithelial cell barriers and permeability depend on the preserva-
tion of adherens and tight junctions (Frisch and Screaton, 2001).
Our data show reduced E-cadherin localization in the FLCN-null
cellular membrane, which might affect adherens junctions.
Hence, we examined whether FLCN is required for the mainte-
nance of cell permeability. Primary AECs isolated from lungs
of Flcnf/f mice were treated with empty adenovirus or Cre-re-
combinase-expressing adenovirus followed by a cell perme-
ability assay using BODIPY-conjugated ouabain (DiPaolo and
Margulies, 2012). Loss of Flcn resulted in increased permeability
of primary AECs (Figure 5H) compared to cells expressing Flcn.
In addition, loss of Flcn was associated with elevated cleaved
caspase-3 levels and an increased number of cells with DNA
fragmentation detected by TUNEL assay (Figures 5I–5K). These
data demonstrate that FLCN is required for the maintenance of
epithelial barrier integrity and AEC survival.
Similarly, mouse epithelial NMuMG cells transfected with
siRNA Flcn exhibited decreased membrane localization of
E-cadherin (Figures 6A and S5A). siFlcn also significantly
decreased protein levels (Figure S5B) and cdh1 (E-cadherin)
Figure 4. FLCN Regulates LKB1 Levels and AMPK Phosphorylation
(A) Primary lung AECs from Flcnf/f mice were infected with control () or Cre-
recombinase-expressing adenovirus (AdCre,+) followed by immunoblot
analysis. See also Figure S3.
(B) Immunoblot analyses of mouse epithelial NMuMG cells transfected with
Flcn siRNA (siFlcn) or control scrambled siRNA ().
(C) Re-expression of FLCN in human FLCN-null UOK-257 cells increases
membrane localization of LKB1.
Top, representative images. Bottom, statistical analyses. Protein ratio for
control cells was taken as 1-fold. Data are mean ± SE (n = 3).and stk11 (LKB1) gene expression (Figures S5D and S5F).
Furthermore, in cells transfected with siFlcn, E-cadherin
does not maintain its multimeric structure as demonstrated
by the presence of lower molecular weight staining under
native conditions (Figure S5C), in contrast to no differences
in LKB1 multimeric structure (Figure S5E) detected by native
gel electrophoresis with equal loading of E-cadherin or LKB1
proteins.
Loss of Flcn in NMuMG cells also reduced transepithelial
resistance (TER) (Figure 6B), another measure of increasedcell permeability (Zheng and Cantley, 2007). We could not use
TER to measure the permeability of primary AECs because
they grow on the Matrigel-coated plates, which impede TER
measurements. Finally, Flcn knockdown in NMuMG cells also
increased cleaved caspase-3 levels (Figure 6C) and apoptosis
(Figure 6D). Analysis of apoptotic gene expression using RT2
Profiler PCR Arrays (SABiosciences; QIAGEN) revealed pro-
apoptotic gene upregulation and decreased expression of
prosurvival genes by Flcn knockdown (Figures S6A–S6C).
Flcn-dependent downregulation of prosurvival Bcl-2 gene was
further confirmed by decreased levels of Bcl-2 protein levels
(Figure S6D). Collectively, our data show that FLCN regulates
membrane localization of E-cadherin, protein, and gene ex-
pression, maintains epithelial barrier function, and preserves
epithelial cell survival.
AICAR and Constitutively Active AMPK Rescue
FLCN-Deficient Cell Survival
Flcn knockdown visibly changes epithelial cell morphology with
disruption of the cell monolayer (Figure 6E). To evaluate the
role of AMPK in FLCN-deficient cell survival, mouse epithelial
NMuMG cells were transfected with siFlcn and then treated
with 5-aminoimidizole-4-carboxamide riboside (AICAR), a cell-
permeable precursor of AMP that activates AMPK (Figure 6G).
Treatment with AICAR reversed Flcn-induced disruption of
epithelial cell morphology (Figure 6E). AICAR treatment also
significantly reduced Flcn-induced DNA fragmentation (Fig-
ure 6H) and epithelial cell death (Figure 6I). Similar results
were seen upon transduction with adenovirus expressing the
constitutively active AMPK (AdAMPK-CA) (Figure 6F) of NMuMG
cells after Flcn knockdown. Expression of constitutively active
AMPK markedly improved Flcn-deficient cell morphology (Fig-
ure 6E), reduced DNA fragmentation (Figure 6H), and rescued
epithelial cell survival (Figure 6I). These results demonstrate
that the kinase activity of AMPK is required for cell survival in
the absence of FLCN.
AICAR Improves Alveolar Surface Tension in
Flcnf/f:SP-C-Cre Mice
Our in vitro and in vivo data show that FLCN controls AEC
survival. Alveolar type II cells are the only cells capable of
manufacturing and secreting phospholipids into alveoli to
reduce surface tension and support alveolar inflation at low
lung volumes. We therefore measured surface tension and
phospholipid composition obtained from bronchoalveolar
lavage (BAL) of Flcnf/f:SP-C-Cre mice on a regular or Dox-sup-
plemented diet. Total phospholipids measured in large aggre-
gate (LA) fractions of BAL from mice with Flcn deletion in
lung epithelium were reduced compared to control mice (Fig-
ure 7A). In addition, we measured surface tension of LA phos-
pholipids by a capillary surfactometer (Guttentag et al., 2005).
The capillary surfactometer measures the ability of airflow to
progress through a fluid-filled capillary. The capillary openness,
as a percentage of capillary diameter, is inversely related to the
surface tension of the fluid in the capillary. LA phospholipids
from Dox-treated Flcnf/f:SP-C-Cre mice exhibited increased
surface tension compared to untreated littermates, as evi-
denced by reduced capillary openness (Figure 7B). Importantly,Cell Reports 7, 412–423, April 24, 2014 ª2014 The Authors 417
Figure 5. Flcn Loss Reduces E-Cadherin
Levels, Increases Cellular Permeability,
and Promotes Apoptosis of Primary Mouse
Lung AECs
(A–C) AdCre-induced Flcn deletion in AECs from
Flcnf/f mice was detected by RT-PCR (A) and
immunoblot (B) with statistical analysis (C). E-
cadherin/tubulin ratio for control cells is taken as
1-fold.
(D) Loss of Flcn in AECs downregulates mem-
brane localization of E-Cadherin (red, top), but not
ZO1 (red, bottom) (as shown in arrowheads). DAPI
(blue) stains nuclei.
See also Figure S4.
(E) Cytoplasmic E-cadherin localization in TSC2-
null epithelial cells.
(F and G) FLCN expression (green) results in
membrane localization of E-cadherin (red) in
TSC2-null cells (F). Data (G) represent percentage
(%) of cells;R60 cells/condition (F).
(H) Flcn deletion increases lung AEC permeability.
Cell permeability in control is taken as 1-fold.
(I and J) Flcn deletion in lung AECs upregulates
cleaved caspase-3.
(K) Flcn deletion in AECs results in DNA frag-
mentation. Number of TUNEL-positive cells to
total number of cells is taken as 100%.
Data are mean ± SE (n > 3).AICAR treatment improved phospholipid content and the sur-
face tension of LA from Dox-treated Flcnf/f:SP-C-Cre mice
(Figures 7A and 7B). There was a trend toward improved
AEC survival, morphology, MLI, and MAAA in Dox-treated
Flcnf/f:SP-C-Cre mice maintained on Dox and treated with
AICAR compared to control mice also treated with AICAR
(Figures 7C and 7E–7G, respectively). Thus, Flcn deletion in
lung epithelium induces a physiologically significant aberration
in surface tension of alveolar phospholipids that is stabilized by
AICAR treatment.
AICAR Suppresses Inflammation and MMP Levels
Increased inflammation and proteolytic degradation of extra-
cellular matrix components such as basement membrane or
interstitial stroma are pathological changes characteristic of
emphysema. To test whether loss of Flcn was associated with
increased inflammation, we examined the BAL fluid for inflam-
matory cell influx. After 2 weeks on a Dox diet, Flcnf/f:SP-C-
Cre mice had increased numbers of total BAL cells compared
with mice on a regular diet that was further increased by 6 weeks
on Dox (Figures S6 and 7D). Importantly, Dox-treated Flcnf/f:SP-
C-Cre mice treated with AICAR exhibited decreased inflamma-
tory cell influx (Figure 7D).418 Cell Reports 7, 412–423, April 24, 2014 ª2014 The AuthorsWe examined the proinflammatory
cytokine profile of BAL from Dox-treated
Flcnf/f:SP-C-Cre mice and untreated lit-
termates to determine whether loss of
FLCN alters cytokine expression. We
found marked elevations in interleukin-6
(IL-6) and macrophage chemotactic pro-tein-1 (MCP-1) in Flcnf/f:SP-C-Cre mice on Dox compared to
untreated littermates (Figures 7H and 7I). There were no sig-
nificant differences between control mice and mice with Flcn
deletion in AECs in the levels of eotaxin, granulocyte-macro-
phage colony-stimulating factor, interferon g, tumor necrosis
factor a, IL-10, IL-13, IL-1b, keratinocyte chemoattractant,
transforming growth factor b1, vascular endothelial growth fac-
tor, and macrophage inflammatory protein 1a (data not shown).
Moreover, AICAR treatment lowered levels of IL-6 and MCP-1 in
BAL fluid of mice with Flcn knockout.
MMPs represent a family of structurally and functionally
related enzymes responsible for the proteolytic degradation of
extracellular matrix and have been mechanistically linked with
progressive pulmonary emphysema and chronic inflammation.
BAL from Dox-treated Flcnf/f:SP-C-Cre mice demonstrated sig-
nificant elevations of MMP-3 andMMP-9 compared to untreated
mice (Figures 7J and 7K). Furthermore, treatment with AICAR
lowered MMP-3 and MMP-9 levels to levels comparable to con-
trol mice (Figures 7J and 7K). Collectively, in vivo experiments
demonstrate that Flcn inactivation in lung AECs of Flcnf/f:SP-C-
Cre mice evokes inflammatory response and upregulation of
MMP-3 and MMP-9 in a manner that is reversible with exoge-
nous AMPK activation by AICAR.
Figure 6. Increased Flcn-Null Epithelial Cell
Apoptosis Is Rescued by AICAR and
Constitutively Active AMPK
(A) Flcn knockdown downregulates membrane
localization of E-cadherin (red). See also Figures
S5 and S6.
(B) Flcn knockdown decreases TER. TER of
siContr-transfected NMuMG cells was taken as
100%.
(C) Cleaved caspase-3 is upregulated by siFlcn.
(D) Flcn knockdown induces DNA fragmentation
(TUNEL assay) of NMuMG cells.
(E) AICAR and constitutively active AMPK (AMPK-
CA) rescue disruption of epithelial cell morphology
caused by siFlcn. Cells were treated either with
100 mM AICAR or diluent, or were infected with
AdAMPK-CA or control adenovirus. Scale bars,
100 mM.
(F and G) Expression of AMPK-CA (F) and AICAR-
induced AMPK and ACC (G) phosphorylation in
epithelial NMuMG cells.
(H and I) DNA fragmentation (H) and epithelial cell
death (I) induced by Flcn loss are rescued by
AICAR andAMPK-CA. Data represent percentage
of TUNEL-positive (H) or dead (I) cells per total
number of cells taken as 100%. Contr, control.
Data are mean ± SE (n = 3).DISCUSSION
The present study identifies FLCN as a regulator of lung homeo-
stasis and advances our understanding of the pathophysiology
of emphysema. This study details the cellular and molecular
mechanisms by which FLCN contributes to lung epithelial cell
survival, thereby maintaining alveolar surface tension through
maintenance of phospholipid production. As such, loss of
FLCN leads to loss of epithelial cells with resultant reduction in
phospholipid production that contributes to the lung changes
associated with BHD (Figure 7L). Furthermore, we show that
FLCN maintains epithelial cell junctions and survival in an
AMPK-dependent fashion by regulating membrane localization
of E-cadherin and LKB1 (Figure 7L).
The abnormal enlargement of airspaces is a major patholog-
ical manifestation of many common and rare lung diseases,
including emphysema, cystic fibrosis, chronic obstructiveCell Reports 7, 412–4pulmonary disease (COPD), pulmonary
lymphangioleiomyomatosis (LAM), pul-
monary Langerhans cell histiocytosis
(PLCH), lymphocytic interstitial pneu-
monia (LIP), follicular bronchiolitis, light-
chain deposition disease, Sjo¨gren’s
syndrome, and amyloidosis (Gupta
et al., 2013). It is becoming increasingly
clear that the mechanisms underlying
the development of emphysematous
changes in the lung are more complex
than simply an imbalance of proteolysis
and antiproteolysis. Together, our data
provide additional supportive evidencefor the complex pathophysiology of emphysematous alveolar
enlargement by showing that FLCN supports cell survival and
influences the cytokine and MMP milieu in ways that might
contribute to lung cyst formation with loss of FLCN in BHD.
These insights into the role of FLCN may serve as a foundation
for novel therapeutic approaches for BHD and other emphyse-
matous lung diseases.
This study establishes that FLCN plays an important physio-
logical role in regulating AEC survival and alveolar integrity. We
demonstrate the importance of FLCN for AEC apoptosis in vivo
and in vitro using Flcnf/f:SP-C-Cre mice, by examining both
lung tissue and isolated AECs. It is intriguing that Flcn loss
in an immortalized mouse embryonic stem cell line resulted in
transcriptional downregulation of proapoptotic protein Bim
(Cash et al., 2011). Elucidating a more direct role for Flcn inter-
secting with apoptotic pathways will be possible in the future
with our cell and mouse models.23, April 24, 2014 ª2014 The Authors 419
Figure 7. AICAR Improves LungHomeosta-
sis of Flcnf/f:SP-C-CreMice with Flcn Dele-
tion in Lung Epithelium
(A) Abnormalities in pulmonary phospholipids in
BAL resulting from Flcn deficiency are restored by
AICAR. Flcnf/f:SP-C-Cre mice on Dox or Dox+
were treated with AICAR or diluent for 6 weeks.
(B) Flcn-induced impairment of surfactant surface
tension is rescued by AICAR.
(C) Flcn loss induces DNA fragmentation of
AECs. Number of TUNEL-positive cells to total
number of cells was taken as 100%.
(D) AICAR normalizes increased inflammatory
cell influx.
(E) H&E staining of Flcnf/f:SP-C-Cre mouse lungs
on Dox or Dox+ treated with AICAR as in (A).
(F and G) Morphometric analyses of Flcnf/f:SP-C-
Cre mouse lungs treated as in (A).
The mean is shown; error bars represent SE
(n > 3). Data for Dox mice are taken as 1-fold.
(H and I) AICAR inhibits IL-6 (H) and MCP-1 (I)
increased by Flcn loss.
(J and K) Upregulation of MMP-3 and MMP-9
induced by Flcn loss in lung epithelium treated as
in (A) is abrogated by AICAR.
(L) A proposed model for the role of FLCN in lung
alveolar homeostasis. FLCN mutations in lung
epithelium downregulate membrane localization
of E-cadherin and LKB1, which impairs AMPK
activation. This model proposes that FLCN plays
an important physiological function to control
AEC survival and maintains alveolar surface
tension. Loss of FLCN results in alveolar collapse
and impairment of lung function.
See also Figure S7. Data in (A)–(K) are represented
as mean ± SEM from two independent experi-
ments (n = 5–7).Our studies clearly demonstrate that the prosurvival role is
mediated through AMPK (Figure 7L). The prosurvival role of
AMPK in epithelial cells is well established, especially as related
to the maintenance of epithelial contacts and polarity (Zhang
et al., 2006; Zheng and Cantley, 2007). Phosphorylation of
AMPK by tumor suppressor LKB1 increases AMPK activity
(Jansen et al., 2009). This requires the localization of LKB1 to
E-cadherin at adherens junctions (Sebbagh et al., 2009). Evi-
dence suggesting a role for AMPK in microtubule formation
via CLIP-170 (Nakano et al., 2010), which also has a role in E-
cadherin localization (Barnes, 2010), provides a reinforcing
loop of E-cadherin/LKB1/AMPK regulation of apical polarity.420 Cell Reports 7, 412–423, April 24, 2014 ª2014 The AuthorsOur data suggest that FLCN promotes
survival of AECs through this E-cadherin/
LKB1/AMPK axis. Our data also suggest
that FLCN functions upstream of AMPK.
Loss of FLCN affects assembly of adhe-
rens junctions via downregulation of E-
cadherin levels while having little effect
on ZO1 levels in tight junctions. Impor-
tantly, disruption of the epithelial mono-
layer and apoptosis caused by FLCN
loss were prevented by either molecularor pharmacological AMPK activation. Together with published
studies, our data suggest that FLCN is required for E-cadherin-
dependent epithelial cell-cell junctions, impairment of LKB1-
AMPK signaling, and caspase-dependent apoptosis of lung
AECs, the initial component of alveolar airspace enlargement.
Further studies will provide detailed mechanisms of how FLCN
regulates E-cadherin and LKB1 expressions.
One consequence of altered AEC survival is the loss of an
important source of pulmonary phospholipids. Phospholipids
play an important role in the maintenance of alveolar stability
through the respiratory cycle, so it is perhaps not surprising
that apoptosis-induced airspace enlargement is associated
with increased alveolar surface tension, and alveolar instability
and collapse (Mouded et al., 2009). However, this raises an
important therapeutic possibility, specifically the potential for
exogenous phospholipid therapy to mitigate the effects of AEC
loss. Although exogenous phospholipid therapy for unintubated
patients is currently unfeasible due to issues of delivery, novel
delivery modalities or therapies targeting increased production
of phospholipid by the remaining epithelial cell population are
attractive options for the future.
The loss of FLCN also evokes an inflammatory response asso-
ciated with local production of inflammatory cytokines and
MMPs. Further studies will determine whether this is due to an
epithelial injury response, or whether FLCN itself signals an
anti-inflammatory pathway.
FLCN acts through an AMPK-mediated pathway that can be
resurrected by exogenous activation of AMPK. AICAR, an
AMPK activator, reverses many of the pathologic changes in
the Flcnf/f:SP-C-Cre mice with Flcn deletion limited to lung
AECs. Importantly, AICAR rescues those features of Flcn loss
that are critical to the pathophysiology of lung cysts, specif-
ically mitigating inflammation and MMP expression that pro-
pagate local alveolar damage and enhancing phospholipid
production to stabilize airspace inflation. Although AMPK-
dependent suppression of MMP-9 has been previously re-
ported by Hwang and Jeong (2010) and Morizane et al.
(2011), our data provide an attractive mechanism for a feedfor-
ward cycle of epithelial cell destabilization with loss of FLCN
followed by further local destruction by enhanced MMP pro-
duction. Further studies are needed to establish the mecha-
nism(s) whereby impaired AMPK signaling increases MMP
expression.
Rescue by AICAR does not reverse the structural changes
due to FLCN loss. It does not rule out the possibility that
AMPK agonists may have a role in prevention or that they
may be useful to stop or slow the progression of existing
emphysema.
There are several limitations of our studies. First, Flcn deletion
in Flcnf/f:SP-C-Cre mice does not precisely phenocopy lung
changes in patients with BHD. Patients with BHD exhibit loss
of alveoli and lung cyst development predominantly localized
to the lower regions of the lung (Gupta et al., 2013). The differ-
ences between our mouse model and human patients may be
due to either the restricted knockout of Flcn in epithelial cells
only or the expression of nonnull mutations of FLCN in patients
with BHD. Despite these limitations, our data demonstrate the
key role of FLCN in the maintenance of normal lung parenchyma
architecture and physiology, and a well-defined mechanism
whereby FLCN, acting through E-cadherin, LKB1, and AMPK,
has a critical role in regulating the assembly of epithelial cell
junctions.EXPERIMENTAL PROCEDURES
The Human Lung Tissue
Control human lung tissues from three subjects were obtained from the
National Disease Research Interchange, and the human BHD tissue samples
from four patients with BHD were obtained from the NIH under approved
protocols.Animals
Flcnf/f:SP-C-Cre mice were generated by crossing Flcnf/f mice (Baba et al.,
2008) with SP-C-rtTA/tetO-Cre (line 2) mice (Perl et al., 2009). Flcnf/f:CCSP-
C-Cre mice were generated by crossing Flcnf/f mice with CCSP-rtTA/tetO-
Cre mice (line 2) (Perl et al., 2009). Genotyping was performed as described
(Baba et al., 2008). Six-week-old male Flcnf/f:SP-C-Cre or Flcnf/f:CCSP-C-
Cre mice were transferred on chow supplemented with 2.5% Dox (Dox+)
or maintained on a regular chow (Dox) for 3 or 6 weeks. Treatment with
500 mg/kg AICAR was performed daily by intraperitoneal injections for
6 weeks in mice on Dox or Dox+ diet.
Lung function wasmeasured on a computerized FlexiVent System (SCIREQ)
(Haczku et al., 2002). For morphological analyses, lungs were inflated at
constant 25 cm H2O pressure with 1:1 optimal cutting temperature/PBS or
low-melting agarose in PBS for approximately 8 min (Goncharova et al.,
2012). Each experimental group included a minimum of five animals per con-
dition. Experiments to determine the effects of Flcn loss on alveoli space
enlargement were performed three times, and experiments with treatment
by AICAR were performed twice. All animal procedures were performed
according to a protocol approved by the University of Pennsylvania IACUC.
BAL Analyses
BAL fluid was collected by lavaging the lung with 1 ml of sterile saline to a
total of 5 ml. Recovered BAL was centrifuged 400 3 g for 10 min at 4C,
then cell pellet was resuspended in 1 ml PBS for total cell count. Cell-free
BAL supernatants were separated by centrifugation at 20,000 3 g for 60 min
at 4C into LA and small-aggregate (SA) phospholipid fractions. Surface
tension was determined by measuring capillary openness with a capillary sur-
factometer (Calmia Medical) (Guttentag et al., 2005). Briefly, 0.5 ml of 1 mg/ml
LA fraction was deposited into the glass capillary and compressed for 120 s,
resulting in a cyclic extrusion from the narrow end of the capillary permitting
airflow and capillary patency. Dysfunctional phospholipids exhibit decreased
capillary patency that is inversely correlated with the surface tension. A micro-
processor calculates the percentage of the 120 s period that the capillary is
open to free airflow. Each sample was analyzed in triplicate. Cytokine and
MMPs were determined in the cell-free BAL by SearchLight Multiplex ELISA
at Aushon Biosystems.
Morphometry
Images of lung tissue sections stained with H&E were acquired with a Nikon
Eclipse 80i microscope under 1003 magnification. Ten randomly selected
fields per slide from three nonserial sections were analyzed. Image-Pro Plus
6.2 software (Media Cybernetics) was used to measure the MAAA and
MLI. Airway, vascular structures, and histological mechanical artifacts were
eliminated from the analysis.
Immunohistochemical, immunocytochemical, and immunoblot analyses
were performed as described (Goncharova et al., 2011). Immunostaining
was visualized with a Leica SP5 X or Zeiss LSM 700 confocal microscope or
a Nikon Eclipse TE2000-E microscope equipped with an Evolution QEi digital
video camera under appropriate filters. Protein levels were analyzed by optical
density with Gel-Pro Analyzer software.
Cell Culture
AECs were isolated from 2-week-old Flcnf/fmice as described (Atochina-Vas-
serman et al., 2011). Mouse lungs were inflated in situ via tracheal cannulation
with dispase. Dissected lobes were digested in modified Eagle’s medium plus
DNase I. The mixed cells were filtered, and fibroblasts were removed from the
suspension by three successive adherence steps on plastic. Negative selec-
tion was used to purify epithelial cells frommacrophages and other blood cells
using magnetic beads (Dynal Mouse T Cell Negative Isolation Kit #114.13D).
Cells were plated in HITES medium (prepared in Ham’s F12 plus 15 mM
HEPES, 0.8 mM CaCl2, hydrocortisone, and b-estradiol) plus 10% fetal calf
serum (FCS) on coverslips coated with 10% Matrigel (BD Biosciences) for
immunofluorescence staining. Serum was added for 48 hr to facilitate adher-
ence and was then removed to minimize overgrowth of any remaining fibro-
blasts. Human UOK-257 and UOK257-2 cell lines (Hong et al., 2010) and
TSC2-null kidney epithelial cells from an Eker rat were prepared as describedCell Reports 7, 412–423, April 24, 2014 ª2014 The Authors 421
by Kleymenova et al. (2001); mouse epithelial NMuMG cells were purchased
from the American Type Culture Collection.
Flcn siRNA was from Dharmacon, and scrambled siRNA was from Santa
Cruz Biotechnology. Transfection was performed using Effectene or RNAiFect
reagents (QIAGEN). Infection with AdCre or AdFLCN adenovirus was
described (Goncharova et al., 2004).
BODIPY Permeability Assay
The assay was performed as described (DiPaolo and Margulies, 2012). Briefly,
2 mmBODIPY-ouabain (Invitrogen) was added to AECs for 1 hr. Then BODIPY-
ouabain fluorescence was visualized using a green emission filter. Fluores-
cence was measured on four separate fields per well, and three wells were
measured per condition. All measurements were normalized to values from
cells infected with control adenovirus.
TER Measurements
TERwasmeasured in confluent NMuMG cells, grown on electric cell substrate
impedance-sensing (ECIS) 8W1E plates, then subjected to an elevated voltage
pulse of 40 kHz frequency, 3.5 V amplitude for 30 s (Taliaferro-Smith et al.,
2009).
Data Analysis
Data points from individual assays represent mean ± SE. Statistically signifi-
cant differences among groups were assessed with ANOVA (with the Fisher
post hoc least significant difference test), with values of p < 0.05 to sufficiently
reject the null hypothesis for all analyses. In Figures 7 and S7, statistically sig-
nificant differences among groups were assessed with t test (n = 5–7 animals
per group). All experiments were designed with matched control conditions
within each experiment (minimum of five animals) to enable statistical com-
parison as paired samples and to obtain statistically significant data.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2014.03.025.
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